<p>上海复星医药（集团）股份有限公司宣布其子公司已获得药品注册批准。根据公司介绍，该批准涵盖一款药品，预计将进一步丰富集团的产品线。公司指出，市场推出后的销售表现可能受到需求、市场竞争和销售渠道等多种因素的影响，建议投资者考虑相关风险。公告中未提及其他受益组织。免责声明：本新闻简报由公共技术（PUBT）使用生成性人工智能创建。尽管 PUBT 努力提供准确及时的信息，但此 AI 生成内容仅供参考，不应被解读为财务、投资或法律建议。上海复星医药（集团）股份有限公司于 2026 年 1 月 22 日通过香港证券交易所（HKex）运营的发行人信息服务（IIS）发布了用于生成本新闻简报的原始内容（参考编号：HKEX-EPS-20260122-11998958），并对此信息承担全部责任。© 版权 2026 - 公共技术（PUBT）</p>

<p>上海复星医药的子公司已获得新药注册批准，增强了集团的产品线。公司提醒，上市后的销售表现可能受到需求、竞争和销售渠道的影响，建议投资者考虑相关风险。公告中未提及其他受益组织</p>

<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that a subsidiary has received approval for drug registration. According to the company, the approval covers a pharmaceutical product and is expected to further enrich the group’s product line. The company noted that the sales performance following market launch may be subject to various factors, including demand, market competition, and sales channels, and investors are advised to consider associated risks. No other beneficiary organizations were mentioned in the announcement. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260122-11998958), on January 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>
<div class="lb-trans"><p>上海复星医药（集团）股份有限公司宣布其子公司已获得药品注册批准。根据公司介绍，该批准涵盖一款药品，预计将进一步丰富集团的产品线。公司指出，市场推出后的销售表现可能受到需求、市场竞争和销售渠道等多种因素的影响，建议投资者考虑相关风险。公告中未提及其他受益组织。免责声明：本新闻简报由公共技术（PUBT）使用生成性人工智能创建。尽管 PUBT 努力提供准确及时的信息，但此 AI 生成内容仅供参考，不应被解读为财务、投资或法律建议。上海复星医药（集团）股份有限公司于 2026 年 1 月 22 日通过香港证券交易所（HKex）运营的发行人信息服务（IIS）发布了用于生成本新闻简报的原始内容（参考编号：HKEX-EPS-20260122-11998958），并对此信息承担全部责任。© 版权 2026 - 公共技术（PUBT）</p>
</div>

上海复星医药的子公司获得了药品注册批准